Reperfusion injury

Tissue damage after return of blood supply following ischemia or hypoxia

Medical condition

Reperfusion injury

Other names| Reperfusion insult
Native records of contractile activity of the left ventricle of isolated rat heart perfused under Langendorff technique. Curve A – contractile function of the heart is greatly depressed after ischemia-reperfusion. Curve B – a set of short ischemic episodes (ischemic preconditioning) before prolonged ischemia provides functional recovery of contractile activity of the heart at reperfusion.
Specialty| Cardiology

Reperfusion injury, sometimes called ischemia-reperfusion injury (IRI) or reoxygenation injury, is the tissue damage caused when blood supply returns to tissue (re- \+ perfusion) after a period of ischemia or lack of oxygen (anoxia or hypoxia). The absence of oxygen and nutrients from blood during the ischemic period creates a condition in which the restoration of circulation results in inflammation and oxidative damage through the induction of oxidative stress rather than (or along with) restoration of normal function.

Reperfusion injury is distinct from cerebral hyperperfusion syndrome (sometimes called "Reperfusion syndrome"), a state of abnormal cerebral vasodilation.

## Causes and importance

[edit]

Reperfusion injury plays a major part in the biochemistry of hypoxic brain injury in stroke. Similar failure processes are involved in brain failure following reversal of cardiac arrest;[1] control of these processes is the subject of ongoing research. Repeated bouts of ischemia and reperfusion injury also are thought to be a factor leading to the formation and failure to heal of chronic wounds such as pressure sores and diabetic foot ulcer.[2] Continuous pressure limits blood supply and causes ischemia, and the inflammation occurs during reperfusion. As this process is repeated, it eventually damages tissue enough to cause a wound.[2]

Reperfusion can cause hyperkalemia.[3]

Reperfusion injury is a primary concern in liver transplantation surgery.[4]

## Mechanisms

[edit]

### Reverse electron transfer and ROS release

[edit]

The main reason for the acute phase of ischemia-reperfusion injury is oxygen deprivation and, therefore, arrest of generation of ATP (cellular energy currency) by mitochondria oxidative phosphorylation. Tissue damage due to the general energy deficit during ischemia is followed by reperfusion (increase of oxygen level) when the injury is enhanced. Mitochondrial complex I is thought to be the most vulnerable enzyme to tissue ischemia/reperfusion but the mechanism of damage is different in different tissues. For example brain ischemia/reperfusion injury is mediated via complex I redox-dependent inactivation.[5] It was found that lack of oxygen leads to conditions in which mitochondrial complex I loses its natural cofactor, flavin mononucleotide (FMN) and become inactive.[6] When oxygen is present the enzyme catalyzes a physiological reaction of NADH oxidation by ubiquinone, supplying electrons downstream of the respiratory chain (complexes III and IV). Ischemia leads to dramatic increase of succinate level.[7] In the presence of succinate mitochondria catalyze reverse electron transfer so that fraction of electrons from succinate is directed upstream to FMN of complex I.[8]

Reverse electron transfer results in a reduction of complex I FMN, increased generation of reactive oxygen species (ROS), followed by a loss of the reduced cofactor (FMNH2) and impairment of mitochondria energy production.[8] The FMN loss by complex I and I/R injury can be alleviated by the administration of FMN precursor, riboflavin.[6]

### Inflammation

[edit]

Reperfusion of ischemic tissues is often associated with microvascular injury, particularly due to increased permeability of capillaries and arterioles that lead to an increase of diffusion and fluid filtration across the tissues. Activated endothelial cells produce more ROS but less nitric oxide following reperfusion, and the imbalance results in a subsequent inflammatory response.[9]

The inflammatory response is partially responsible for the damage of reperfusion injury. White blood cells, carried to the area by the newly returning blood, release a host of inflammatory factors such as interleukins as well as free radicals in response to tissue damage.[10] The restored blood flow reintroduces oxygen within cells that damages cellular proteins, DNA, and the plasma membrane. Damage to the cell's membrane may in turn cause the release of more free radicals. Such reactive species may also act indirectly in redox signaling to turn on apoptosis. White blood cells may also bind to the endothelium of small capillaries, obstructing them and leading to more ischemia.[10]

## Treatment

[edit]

Main article: Reperfusion therapy

### Therapeutic hypothermia

[edit]

See also: Hypothermia therapy for neonatal encephalopathy

The therapeutic effect of hypothermia is not confined to metabolism and membrane stability. Hypothermia can also prevent the injuries that occur after circulation returns to the brain, or what is termed reperfusion injuries. In fact, an individual suffering from an ischemic insult continues suffering injuries well after circulation is restored. In rats, it has been shown that neurons often die a full 24 hours after blood flow returns. Some theorize that this delayed reaction derives from the various inflammatory immune responses that occur during reperfusion.[11] These inflammatory responses cause intracranial pressure, pressure which leads to cell injury and in some situations cell death. Hypothermia has been shown to help moderate intracranial pressure and therefore to minimize the harmful effect of a patient's inflammatory immune responses during reperfusion. Beyond this, reperfusion also increases free radical production. Hypothermia too has been shown to minimize a patient's production of deadly free radicals during reperfusion. Many now suspect it is because hypothermia reduces both intracranial pressure and free radical production that hypothermia improves patient outcome following a blockage of blood flow to the brain.[12]

### Remote ischemic conditioning

[edit]

Causing repeated, temporary cessation of blood flow to a limb to create ischemia (lack of oxygen and glucose) in the tissue appears to protect against ischemic and reperfusion injury in animals.[13] Although noted to have some benefits in experimental models in animals, this is still an experimental procedure in humans and initial evidence from small studies have not been replicated in larger clinical trials. Successive clinical trials have failed to identify evidence supporting a protective role in humans as of 2015.[14] Two large human studies completed in 2023 had re-ignited interest in this technique with positive results.[15]

### Edaravone

[edit]

Edaravone is approved as an adjuvant treatment for stroke in Japan. It appears to improve outcomes when added to reperfusion therapy.[16] It is known to reduce reperfusion injury in animal models and presumably it also helps human patients by reducing reperfusion injury. It can be taken intravenously[17] or by mouth.

Edaravone is combined with dextro-borneol (dexborneol) in edaravone/dexborneol, a drug approved in China for stroke. It is approved in intravenous (2021) and sublingual (2025) forms. The intravenous combination was approved on the basis of trials showing it to be superior to edavarone alone.[18][19]

### Hydrogen sulfide treatment

[edit]

There are some preliminary studies in mice that seem to indicate that treatment with hydrogen sulfide (H2S) can have a protective effect against reperfusion injury.[20]

### Cyclosporin

[edit]

In addition to its well-known immunosuppressive capabilities, the one-time administration of cyclosporin at the time of percutaneous coronary intervention (PCI) has been found to deliver a 40 percent reduction in infarct size in a small group proof of concept study of human patients with reperfusion injury published in The New England Journal of Medicine in 2008.[21]

Cyclosporin has been confirmed in studies to inhibit the actions of cyclophilin D, a protein which is induced by excessive intracellular calcium flow to interact with other pore components and help open the MPT pore. Inhibiting cyclophilin D has been shown to prevent the opening of the MPT pore and protect the mitochondria and cellular energy production from excessive calcium inflows.[22]

However, the studies CIRCUS and CYCLE (published in September 2015 and February 2016 respectively) looked at the use of cyclosporin as a one time IV dose given right before perfusion therapy (PCI). Both studies found there is no statistical difference in outcome with cyclosporin administration.[23][24]

Reperfusion leads to biochemical imbalances within the cell that lead to cell death and increased infarct size. More specifically, calcium overload and excessive production of reactive oxygen species in the first few minutes after reperfusion set off a cascade of biochemical changes that result in the opening of the so-called mitochondrial permeability transition pore (MPT pore) in the mitochondrial membrane of cardiac cells.[22]

The opening of the MPT pore leads to the inrush of water into the mitochondria, resulting in mitochondrial dysfunction and collapse. Upon collapse, the calcium is then released to overwhelm the next mitochondria in a cascading series of events that cause mitochondrial energy production supporting the cell to be reduced or stopped completely. The cessation of energy production results in cellular death. Protecting mitochondria is a viable cardioprotective strategy.[25]

In 2008, an editorial in the New England Journal of Medicine called for more studies to determine if cyclosporin can become a treatment to ameliorate reperfusion injury by protecting mitochondria.[25] To that end, in 2011 the researchers involved in the original 2008 NEJM study initiated a phase III clinical study of reperfusion injury in 1000 myocardial infarction patients in centers throughout Europe. Results of that study were announced in 2015 and indicated that "intravenous cyclosporine did not result in better clinical outcomes than those with placebo and did not prevent adverse left ventricular remodeling at 1 year."[23] This same process of mitochondrial destruction through the opening of the MPT pore is implicated in making traumatic brain injuries much worse.[26]

### TRO40303

[edit]

TRO40303 is a new cardioprotective compound that was shown to inhibit the MPT pore and reduce infarct size after ischemia-reperfusion. It was developed by Trophos company and currently is in Phase I clinical trial.[27]

### Stem cell therapy

[edit]

Recent investigations suggest a possible beneficial effect of mesenchymal stem cells on heart and kidney reperfusion injury.[28][29]

### Superoxide dismutase

[edit]

Superoxide dismutase is an effective anti-oxidant enzyme which converts superoxide anions to water and hydrogen peroxide. Recent researches have shown significant therapeutic effects on pre-clinical models of reperfusion injury after ischemic stroke.[30][31]

### Metformin

[edit]

A series of 2009 studies published in the Journal of Cardiovascular Pharmacology suggest that Metformin may prevent cardiac reperfusion injury by inhibition of Mitochondrial Complex I and the opening of MPT pore and in rats.[32][33]

### Riboflavin

[edit]

In neonatal in vivo model of brain ischemia/reperfusion, tissue injury can be alleviated by the administration of FMN precursor, riboflavin that prevents inactivation of mitochondrial complex I.[6][34]

### Cannabinoids

[edit]

A study published in 2012 show that the synthetic analogue of the phytocannabinoid Tetrahydrocannabivarin (THCV), Δ8-Tetrahydrocannabivarin (Δ8-THCV) and its metabolite 11-OH-Δ8-THCV, prevent hepatic ischaemia/reperfusion injury by decreasing oxidative stress and inflammatory responses through cannabinoid CB2 receptors and thereby decrease tissue injury and inflammation with a protective effect against liver damage. Pretreatment with a CB2 receptor antagonist attenuated the protective effects of Δ8-THCV, while a CB1 antagonist tended to enhance it.[35]

An earlier study published in 2011 found, that Cannabidiol (CBD) also protects against hepatic ischemia/reperfusion injury by attenuating inflammatory signaling and response of oxidative and nitrative stress, and thereby cell death and tissue injury, but independent from classical CB1 and CB2 receptors.[36]

## Reperfusion protection in obligate hibernators

[edit]

Obligatory hibernators such as the ground squirrels show resistance to ischemia/reperfusion (I/R) injury in liver, heart, and small intestine during the hibernation season when there is a switch from carbohydrate metabolism to lipid metabolism for cellular energy supply.[37][38][39] This metabolic switch limits anaerobic metabolism and the formation of lactate, a herald of poor prognosis and multi-organ failure (MOF) after I/R injury. In addition, the increase in lipid metabolism generates ketone bodies and activates peroxisome proliferating-activated receptors (PPARs), both of which have been shown to be protective against I/R injury.[40]

## See also

[edit]

* Crush syndrome
* Ischemic stroke
* Myocardial infarction — Reperfusion
* Therapeutic hypothermia
* Hypothermia therapy for neonatal encephalopathy
* Remote ischemic conditioning
* Ischemia-reperfusion injury of the appendicular musculoskeletal system

## References

[edit]

1. ^ Hendry, Robert; Crippen, David (2007). "Brain failure and brain death". In Fink, Mitchell P.; Jurkovic, Gregory J. (eds.). ACS Surgery: Principles and Practice. B C Decker. pp. 1609–1612\. ISBN 978-1-55009-399-5.
2. ^ a b Mustoe, Thomas (May 2004). "Understanding chronic wounds: a unifying hypothesis on their pathogenesis and implications for therapy". The American Journal of Surgery. 187 (5): S65 – S70. doi:10.1016/S0002-9610(03)00306-4. PMID 15147994.
3. ^ Atlee, John L. (2007). Complications in Anesthesia. Elsevier Health Sciences. pp. 55–. ISBN 978-1-4160-2215-2.
4. ^ Lemasters and, John J.; Thurman, Ronald G. (April 1997). "Reperfusion injury after liver preservation for transplantation". Annual Review of Pharmacology and Toxicology. 37 (1): 327–338\. doi:10.1146/annurev.pharmtox.37.1.327. PMID 9131256.
5. ^ Galkin, A (November 2019). "Brain Ischemia/Reperfusion Injury and Mitochondrial Complex I Damage". Biochemistry. Biokhimiia. 84 (11): 1411–1423\. doi:10.1134/S0006297919110154. PMID 31760927. S2CID 207990089.
6. ^ a b c Stepanova, Anna; Sosunov, Sergey; Niatsetskaya, Zoya; Konrad, Csaba; Starkov, Anatoly A.; Manfredi, Giovanni; Wittig, Ilka; Ten, Vadim; Galkin, Alexander (20 September 2019). "Redox-Dependent Loss of Flavin by Mitochondrial Complex I in Brain Ischemia/Reperfusion Injury". Antioxidants & Redox Signaling. 31 (9): 608–622\. doi:10.1089/ars.2018.7693. PMC 6657304. PMID 31037949.
7. ^ Sahni, Prateek V; Zhang, Jimmy; Sosunov, Sergey; Galkin, Alexander; Niatsetskaya, Zoya; Starkov, Anatoly; Brookes, Paul S; Ten, Vadim S (February 2018). "Krebs cycle metabolites and preferential succinate oxidation following neonatal hypoxic-ischemic brain injury in mice". Pediatric Research. 83 (2): 491–497\. doi:10.1038/pr.2017.277. PMC 5866163. PMID 29211056.
8. ^ a b Stepanova, Anna; Kahl, Anja; Konrad, Csaba; Ten, Vadim; Starkov, Anatoly S; Galkin, Alexander (December 2017). "Reverse electron transfer results in a loss of flavin from mitochondrial complex I: Potential mechanism for brain ischemia reperfusion injury". Journal of Cerebral Blood Flow & Metabolism. 37 (12): 3649–3658\. doi:10.1177/0271678X17730242. PMC 5718331. PMID 28914132.
9. ^ Carden, Donna L.; Granger, D. Neil (February 2000). "Pathophysiology of ischaemia-reperfusion injury". The Journal of Pathology. 190 (3): 255–266\. doi:10.1002/(SICI)1096-9896(200002)190:3<255::AID-PATH526>3.0.CO;2-6. PMID 10685060. S2CID 37383438.
10. ^ a b Reperfusion Injury in Stroke at eMedicine
11. ^ "Back to Life: The Science of Reviving the Dead". Newsweek. 22 July 2007.
12. ^ Polderman, Kees H. (1 April 2004). "Application of therapeutic hypothermia in the ICU: opportunities and pitfalls of a promising treatment modality. Part 1: Indications and evidence". Intensive Care Medicine. 30 (4): 556–575\. doi:10.1007/s00134-003-2152-x. PMID 14767591. S2CID 5733761.
13. ^ Heusch, Gerd (2015-02-13). "Molecular Basis of Cardioprotection Signal Transduction in Ischemic Pre-, Post-, and Remote Conditioning". Circulation Research. 116 (4): 674–699\. doi:10.1161/CIRCRESAHA.116.305348. ISSN 0009-7330. PMID 25677517.
14. ^ Remote Ischemic Preconditioning and Outcomes of Cardiac Surgery. NEJM. October 5, 2015.
15. ^ Zhao, Wenbo; Hausenloy, Derek J.; Hess, David C.; Yellon, Derek M.; Ji, Xunming (August 2023). "Remote Ischemic Conditioning: Challenges and Opportunities". Stroke. 54 (8): 2204–2207\. doi:10.1161/STROKEAHA.123.043279.
16. ^ Miyaji Y, Yoshimura S, Sakai N, Yamagami H, Egashira Y, Shirakawa M, et al. (2015). "Effect of edaravone on favorable outcome in patients with acute cerebral large vessel occlusion: subanalysis of RESCUE-Japan Registry". Neurologia Medico-Chirurgica. 55 (3). Tokyo: 241–247\. doi:10.2176/nmc.ra.2014-0219. PMC 4533339. PMID 25739433.
17. ^ Enomoto, Masaya; Endo, Akira; Yatsushige, Hiroshi; Fushimi, Kiyohide; Otomo, Yasuhiro (March 2019). "Clinical Effects of Early Edaravone Use in Acute Ischemic Stroke Patients Treated by Endovascular Reperfusion Therapy". Stroke. 50 (3): 652–658\. doi:10.1161/STROKEAHA.118.023815.
18. ^ Xu, Jie; Wang, Anxin; Meng, Xia; Yalkun, Gulbahram; Xu, Anding; Gao, Zhiqiang; Chen, Huisheng; Ji, Yong; Xu, Jun; Geng, Deqin; Zhu, Runxiu; Liu, Bo; Dong, Aiqin; Mu, Hua; Lu, Zhihong; Li, Shuya; Zheng, Huaguang; Chen, Xia; Wang, Yilong; Zhao, Xingquan; Wang, Yongjun; Wang, Yongjun; Xu, Anding; Zhao, Xingquan; Chen, Xia; Wang, Yongjun; Meng, Xia; Wang, Yilong; Xu, Jie; Wang, Anxin; Zheng, Huaguang; Gao, Zhiqiang; Duan, Lei; Zhang, Jinghua; Li, Shuya; Lou, Donghua; Gao, Zhiqiang; Chen, Huisheng; Ji, Yong; Xu, Jun; Geng, Deqin; Zhu, Runxiu; Liu, Bo; Dong, Aiqin; Liang, Qingcheng; Yang, Hong; Guo, Cunju; Li, Xin; He, Mingli; Tian, Xiangyang; Cui, Yong; Zhou, Junshan; Wang, Ning; Wang, Lei; Zhang, Xinjiang; Gao, Xiaoping; Lu, Liping; Li, Tong; Cheng, Yan; Liu, Kaixiang; Xi, Xiaokun; Wang, Baojun; Sun, Lin; Zhao, Shigang; Chu, Xiaofan; Lian, Yajun; Yan, Fuling; Wang, Xiaoshan; Wang, Dong; Shao, Bei; Jiao, Jinsong; Wu, Heng; Li, Guanglai; Guo, Libin; Wang, Yongjun; Pan, Suyue; Xu, Anding; Li, Heng; Zhuang, Jianhua; Li, Xin; Wu, Jun; Wang, Anxin; Lou, Donghua; Zuo, Yingting; Zhang, Yijun; Zhang, Xiaoli; Feng, Xiaofei; Meng, Xia; Wang, David; Dong, Kehui; Liu, Yanfang; Li, Hao; Chen, Dawei; Lv, Qiushi (March 2021). "Edaravone Dexborneol Versus Edaravone Alone for the Treatment of Acute Ischemic Stroke: A Phase III, Randomized, Double-Blind, Comparative Trial". Stroke. 52 (3): 772–780\. doi:10.1161/STROKEAHA.120.031197. PMID 33588596.
19. ^ Fu, Yu; Wang, Anxin; Tang, Renhong; Li, Shuya; Tian, Xue; Xia, Xue; Ren, Jinsheng; Yang, Shibao; Chen, Rong; Zhu, Shunwei; Feng, Xiaofei; Yao, Jinliang; Wei, Yan; Dong, Xueshuang; Ling, Yun; Yi, Fei; Deng, Qian; Guo, Cunju; Sui, Yi; Han, Shugen; Wen, Guoqiang; Li, Chuanling; Dong, Aiqin; Sun, Xin; Wang, Zhimin; Shi, Xueying; Liu, Bo; Fan, Dongsheng (1 April 2024). "Sublingual Edaravone Dexborneol for the Treatment of Acute Ischemic Stroke: The TASTE-SL Randomized Clinical Trial". JAMA Neurology. 81 (4): 319. doi:10.1001/jamaneurol.2023.5716.
20. ^ Elrod, John W; Calvert, John W; Duranski, Mark R; Lefer, David J (31 October 2006). "Abstract 947: Hydrogen Sulfide Donor Protects Against Acute Myocardial Ischemia-Reperfusion Injury". Circulation. 114 (suppl_18): II_172. doi:10.1161/circ.114.suppl_18.II_172-a (inactive 1 July 2025).`{{cite journal}}`: CS1 maint: DOI inactive as of July 2025 (link)
21. ^ Piot, Christophe; Croisille, Pierre; Staat, Patrick; Thibault, Hélène; Rioufol, Gilles; Mewton, Nathan; Elbelghiti, Rachid; Cung, Thien Tri; Bonnefoy, Eric; Angoulvant, Denis; Macia, Christophe; Raczka, Franck; Sportouch, Catherine; Gahide, Gerald; Finet, Gérard; André-Fouët, Xavier; Revel, Didier; Kirkorian, Gilbert; Monassier, Jean-Pierre; Derumeaux, Geneviève; Ovize, Michel (31 July 2008). "Effect of Cyclosporine on Reperfusion Injury in Acute Myocardial Infarction". New England Journal of Medicine. 359 (5): 473–481\. doi:10.1056/NEJMoa071142. PMID 18669426.
22. ^ a b Javadov, Sabzali; Karmazyn, Morris (2007). "Mitochondrial Permeability Transition Pore Opening as an Endpoint to Initiate Cell Death and as a Putative Target for Cardioprotection". Cellular Physiology and Biochemistry. 20 (1–4): 1–22\. doi:10.1159/000103747. PMID 17595511. S2CID 1949575.1–4&rft.pages=1-22&rft.date=2007&rft_id=https://api.semanticscholar.org/CorpusID:1949575#id-name=S2CID&rft_id=info:pmid/17595511&rft_id=info:doi/10.1159/000103747&rft.aulast=Javadov&rft.aufirst=Sabzali&rft.au=Karmazyn,+Morris&rft_id=https://doi.org/10.1159%2F000103747&rfr_id=info:sid/en.wikipedia.org:Reperfusion+injury" class="Z3988">
23. ^ a b Cung, Thien-Tri; Morel, Olivier; Cayla, Guillaume; Rioufol, Gilles; Garcia-Dorado, David; Angoulvant, Denis; Bonnefoy-Cudraz, Eric; Guérin, Patrice; Elbaz, Meier; Delarche, Nicolas; Coste, Pierre; Vanzetto, Gerald; Metge, Marc; Aupetit, Jean-François; Jouve, Bernard; Motreff, Pascal; Tron, Christophe; Labeque, Jean-Noel; Steg, Philippe Gabriel; Cottin, Yves; Range, Grégoire; Clerc, Jérome; Claeys, Marc J.; Coussement, Patrick; Prunier, Fabrice; Moulin, Frédéric; Roth, Olivier; Belle, Loïc; Dubois, Philippe; Barragan, Paul; Gilard, Martine; Piot, Christophe; Colin, Patrice; De Poli, Fabien; Morice, Marie-Claude; Ider, Omar; Dubois-Randé, Jean-Luc; Unterseeh, Thierry; Le Breton, Hervé; Béard, Thierry; Blanchard, Didier; Grollier, Gilles; Malquarti, Vincent; Staat, Patrick; Sudre, Arnaud; Elmer, Eskil; Hansson, Magnus J.; Bergerot, Cyrille; Boussaha, Inesse; Jossan, Claire; Derumeaux, Geneviève; Mewton, Nathan; Ovize, Michel (10 September 2015). "Cyclosporine before PCI in Patients with Acute Myocardial Infarction". New England Journal of Medicine. 373 (11): 1021–1031\. doi:10.1056/NEJMoa1505489. hdl:10044/1/41761. PMID 26321103.
24. ^ Ottani, Filippo; Latini, Roberto; Staszewsky, Lidia; La Vecchia, Luigi; Locuratolo, Nicola; Sicuro, Marco; Masson, Serge; Barlera, Simona; Milani, Valentina; Lombardi, Mario; Costalunga, Alessandra; Mollichelli, Nadia; Santarelli, Andrea; De Cesare, Nicoletta; Sganzerla, Paolo; Boi, Alberto; Maggioni, Aldo Pietro; Limbruno, Ugo (February 2016). "Cyclosporine A in Reperfused Myocardial Infarction". Journal of the American College of Cardiology. 67 (4): 365–374\. doi:10.1016/j.jacc.2015.10.081. PMID 26821623. S2CID 205575155.
25. ^ a b Hausenloy, Derek J.; Yellon, Derek M. (31 July 2008). "Time to Take Myocardial Reperfusion Injury Seriously". New England Journal of Medicine. 359 (5): 518–520\. doi:10.1056/NEJMe0803746. PMID 18669431.
26. ^ Sullivan, Patrick G.; Sebastian, Andrea H.; Hall, Edward D. (February 2011). "Therapeutic Window Analysis of the Neuroprotective Effects of Cyclosporine A after Traumatic Brain Injury". Journal of Neurotrauma. 28 (2): 311–318\. doi:10.1089/neu.2010.1646. PMC 3037811. PMID 21142667.
27. ^ Le Lamer, Sophie; Paradis, Stéphanie; Rahmouni, Hidayat; Chaimbault, Corinne; Michaud, Magali; Culcasi, Marcel; Afxantidis, Jean; Latreille, Mathilde; Berna, Patrick; Berdeaux, Alain; Pietri, Sylvia; Morin, Didier; Donazzolo, Yves; Abitbol, Jean-Louis; Pruss, Rebacca M; Schaller, Sophie (December 2014). "Translation of TRO40303 from myocardial infarction models to demonstration of safety and tolerance in a randomized Phase I trial". Journal of Translational Medicine. 12 (1): 38. doi:10.1186/1479-5876-12-38. PMC 3923730. PMID 24507657.
28. ^ van der Spoel, T. I. G.; Jansen of Lorkeers, S. J.; Agostoni, P.; van Belle, E.; Gyongyosi, M.; Sluijter, J. P. G.; Cramer, M. J.; Doevendans, P. A.; Chamuleau, S. A. J. (1 September 2011). "Human relevance of pre-clinical studies in stem cell therapy: systematic review and meta-analysis of large animal models of ischaemic heart disease". Cardiovascular Research. 91 (4): 649–658\. doi:10.1093/cvr/cvr113. PMID 21498423.
29. ^ Zhao, Jing-Jie; Liu, Jun-Li; Liu, Ling; Jia, Hong-Ying (January 2014). "Protection of mesenchymal stem cells on acute kidney injury". Molecular Medicine Reports. 9 (1): 91–96\. doi:10.3892/mmr.2013.1792. PMID 24220681.
30. ^ Jiang, Yuhang; Arounleut, Phonepasong; Rheiner, Steven; Bae, Younsoo; Kabanov, Alexander V.; Milligan, Carol; Manickam, Devika S. (2016-06-10). "SOD1 nanozyme with reduced toxicity and MPS accumulation". Journal of Controlled Release. Thirteenth International Nanomedicine and Drug Delivery Symposium. 231: 38–49\. doi:10.1016/j.jconrel.2016.02.038. PMID 26928528.
31. ^ Jiang, Yuhang; Brynskikh, Anna M.; S-Manickam, Devika; Kabanov, Alexander V. (2015-09-10). "SOD1 nanozyme salvages ischemic brain by locally protecting cerebral vasculature". Journal of Controlled Release. 213: 36–44\. doi:10.1016/j.jconrel.2015.06.021. PMC 4684498. PMID 26093094.
32. ^ Paiva, Marta; Riksen, Niels P; Davidson, Sean M; Hausenloy, Derek J; Monteiro, Pedro; Gonçalves, Lino; Providência, Luís; Rongen, Gerard A; Smits, Paul; Mocanu, Mihaela M; Yellon, Derek M (May 2009). "Metformin Prevents Myocardial Reperfusion Injury by Activating the Adenosine Receptor". Journal of Cardiovascular Pharmacology. 53 (5): 373–378\. doi:10.1097/FJC.0b013e31819fd4e7. PMID 19295441. S2CID 21161059.
33. ^ Bhamra, Gurpreet S.; Hausenloy, Derek J.; Davidson, Sean M.; Carr, Richard D.; Paiva, Marta; Wynne, Abigail M.; Mocanu, Mihaela M.; Yellon, Derek M. (May 2008). "Metformin protects the ischemic heart by the Akt-mediated inhibition of mitochondrial permeability transition pore opening". Basic Research in Cardiology. 103 (3): 274–284\. doi:10.1007/s00395-007-0691-y. PMID 18080084. S2CID 28815693.
34. ^ Ten, Vadim; Galkin, Alexander (October 2019). "Mechanism of mitochondrial complex I damage in brain ischemia/reperfusion injury. A hypothesis". Molecular and Cellular Neuroscience. 100 103408\. doi:10.1016/j.mcn.2019.103408. PMC 11500760. PMID 31494262. S2CID 201835094.
35. ^ Bátkai, Sándor; Mukhopadhyay, Partha; Horváth, Bėla; Rajesh, Mohanraj; Gao, Rachel Y; Mahadevan, Anu; Amere, Mukkanti; Battista, Natalia; Lichtman, Aron H; Gauson, Lisa A; Maccarrone, Mauro; Pertwee, Roger G; Pacher, Pál (April 2012). "Δ8-Tetrahydrocannabivarin prevents hepatic ischaemia/reperfusion injury by decreasing oxidative stress and inflammatory responses through cannabinoid CB2 receptors: Δ8-Tetrahydrocannabivarin for reperfusion injury". British Journal of Pharmacology. 165 (8): 2450–2461\. doi:10.1111/j.1476-5381.2011.01410.x. PMC 3423240. PMID 21470208.
36. ^ Mukhopadhyay, Partha; Rajesh, Mohanraj; Horváth, Béla; Bátkai, Sándor; Park, Ogyi; Tanchian, Galin; Gao, Rachel Y.; Patel, Vivek; Wink, David A.; Liaudet, Lucas; Haskó, György; Mechoulam, Raphael; Pacher, Pál (May 2011). "Cannabidiol protects against hepatic ischemia/reperfusion injury by attenuating inflammatory signaling and response, oxidative/nitrative stress, and cell death". Free Radical Biology and Medicine. 50 (10): 1368–1381\. doi:10.1016/j.freeradbiomed.2011.02.021. PMC 3081988. PMID 21362471.
37. ^ Dark, J (2005). "Annual lipid cycles in hibernators: integration of physiology and behavior". Annual Review of Nutrition. 25: 469–97\. doi:10.1146/annurev.nutr.25.050304.092514. PMID 16011475.
38. ^ Andrews, MT (May 2007). "Advances in molecular biology of hibernation in mammals". BioEssays. 29 (5): 431–40\. doi:10.1002/bies.20560. PMID 17450592. S2CID 22894246.
39. ^ Kurtz, Courtney C.; Lindell, Susanne L.; Mangino, Martin J.; Carey, Hannah V. (November 2006). "Hibernation confers resistance to intestinal ischemia-reperfusion injury". American Journal of Physiology. Gastrointestinal and Liver Physiology. 291 (5): G895 – G901. doi:10.1152/ajpgi.00155.2006. PMID 16751173.
40. ^ Zingarelli, Basilia; Hake, Paul W.; O’Connor, Michael; Burroughs, Timothy J.; Wong, Hector R.; Solomkin, Joseph S.; Lentsch, Alex B. (June 2009). "Lung injury after hemorrhage is age dependent: Role of peroxisome proliferator-activated receptor γ". Critical Care Medicine. 37 (6): 1978–1987\. doi:10.1097/CCM.0b013e31819feb4d. PMC 2765201. PMID 19384226.

## External links

[edit]

Classification|

* MeSH: D015427

|

External resources|

* Scholia: Q1413991

* v
* t
* e

Cardiovascular disease (vessels)

Arteries, arterioles
and capillaries|

| Inflammation|

* Arteritis
* Aortitis
* Buerger's disease

|

Arteriosclerosis|

* Atherosclerosis
* Foam cell
* Fatty streak
* Atheroma
* Cholesterol
* LDL
* Oxycholesterol
* Trans fat
* Monckeberg's arteriosclerosis
* Hyaline arteriolosclerosis
* Hyperplastic arteriolosclerosis

Peripheral artery disease|

* Stenosis
* Carotid artery stenosis
* Renal artery stenosis
* Aortoiliac occlusive disease
* Critical limb ischemia
* Degos disease
* Erythromelalgia
* Fibromuscular dysplasia
* Hepatic artery thrombosis
* Intermittent claudication
* Raynaud's phenomenon

Aneurysm / dissection /
pseudoaneurysm|

* torso: Aortic aneurysm
* Abdominal aortic aneurysm
* Thoracic aortic aneurysm
* Aneurysm of sinus of Valsalva
* Aortic dissection
* Aortic rupture
* Coronary artery aneurysm
* head / neck
* Intracranial aneurysm
* Intracranial berry aneurysm
* Carotid artery dissection
* Vertebral artery dissection
* Familial aortic dissection

Vascular malformation|

* Arteriovenous fistula
* Arteriovenous malformation
* Telangiectasia
* Hereditary hemorrhagic telangiectasia
* Generalized essential telangiectasia

Vascular nevus|

* Cherry hemangioma
* Halo nevus
* Spider angioma

Veins|

| Inflammation|

* Phlebitis

|

Venous thrombosis /
Thrombophlebitis|

* primarily lower limb
* Deep vein thrombosis
* abdomen
* Hepatic veno-occlusive disease
* Budd–Chiari syndrome
* May–Thurner syndrome
* Portal vein thrombosis
* Renal vein thrombosis
* upper limb / torso
* Mondor's disease
* Paget–Schroetter disease
* Pulmonary embolism
* head
* Cerebral venous sinus thrombosis
* Post-thrombotic syndrome

Varicose veins|

* Gastric varices
* Portacaval anastomosis
* Caput medusae
* Esophageal varices
* Hemorrhoid
* Varicocele

Other|

* Chronic venous insufficiency
* Chronic cerebrospinal venous insufficiency
* Superior vena cava syndrome
* Inferior vena cava syndrome
* Venous ulcer

Arteries or veins|

* Angiopathy
* Macroangiopathy
* Microangiopathy
* Embolism
* Pulmonary embolism
* Cholesterol embolism
* Paradoxical embolism
* Thrombosis
* Vasculitis

Blood pressure|

| Hypertension|

* Hypertensive heart disease
* Hypertensive emergency
* Hypertensive nephropathy
* Essential hypertension
* Secondary hypertension
* Renovascular hypertension
* Benign hypertension
* Pulmonary hypertension
* Systolic hypertension
* White coat hypertension

|

Hypotension|

* Orthostatic hypotension
* Shock (circulatory)

Authority control databases: National |

* Poland

|

*[v]: View this template
*[t]: Discuss this template
*[e]: Edit this template